via Rensselaer Polytechnic Institute
Heparin, a common anticoagulant, could also form the basis of a viral trap for SARS-CoV-2
In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. Heparin, a common blood thinner, and a heparin variant stripped of its anticoagulant properties, performed on par with remdesivir in inhibiting SARS-CoV-2 infection in mammalian cells.
Published online today in Cell Discovery, the research is the latest example of a decoy strategy researchers from the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.
The spike protein on the surface of SARS-CoV-2 latches onto the ACE-2 receptor, a molecule on the surface of human cells. Once secured, the virus inserts its own genetic material into the cell, hijacking the cellular machinery to produce replica viruses. But the virus could just as easily be persuaded to lock onto a decoy molecule that offers a similar fit. The neutralized virus would be trapped and eventually degrade naturally.
Previous research has shown this decoy technique works in trapping other viruses, including dengue, Zika, and influenza A.
“We’re learning how to block viral infection, and that is knowledge we are going to need if we want to rapidly confront pandemics,” said Jonathan Dordick, the lead researcher and a professor of chemical and biological engineering at Rensselaer Polytechnic Institute. “The reality is that we don’t have great antivirals. To protect ourselves against future pandemics, we are going to need an arsenal of approaches that we can quickly adapt to emerging viruses.”
The Cell Discovery paper tests antiviral activity in three variants of heparin (heparin, trisulfated heparin, and a non-anticoagulant low molecular weight heparin) and two fucoidans (RPI-27 and RPI-28) extracted from seaweed. All five compounds are long chains of sugar molecules known as sulfated polysaccharides, a structural conformation that the results of a binding study published earlier this month in Antiviral Research suggested as an effective decoy.
The researchers performed a dose response study known as an EC50 — shorthand for the effective concentration of the compound that inhibits 50% of viral infectivity — with each of the five compounds on mammalian cells. For the results of an EC50, which are given in a molar concentration, a lower value signals a more potent compound.
RPI-27 yielded an EC50 value of approximately 83 nanomolar, while a similar previously published and independent in vitro test of remdesivir on the same mammalian cells yielded an EC50 of 770 nanomolar. Heparin yielded an EC50 of 2.1 micromolar, or about one-third as active as remdesivir, and a non-anticoagulant analog of heparin yielded an EC50 of 5.0 micromolar, about one-fifth as active as remdesivir.
A separate test found no cellular toxicity in any of the compounds, even at the highest concentrations tested.
“What interests us is a new way of getting at infection,” said Robert Linhardt, a Rensselaer professor of chemistry and chemical biology who is collaborating with Dordick to develop the decoy strategy. “The current thinking is that the COVID-19 infection starts in the nose, and either of these substances could be the basis for a nasal spray. If you could simply treat the infection early, or even treat before you have the infection, you would have a way of blocking it before it enters the body.”
Dordick added that compounds from seaweed “could serve as a basis for an oral delivery approach to address potential gastrointestinal infection.”
In studying SARS-CoV-2 sequencing data, Dordick and Linhardt recognized several motifs on the structure of the spike protein that promised a fit compatible with heparin, a result borne out in the binding study. The spike protein is heavily encrusted in glycans, an adaptation that protects it from human enzymes which could degrade it, and prepares it to bind with a specific receptor on the cell surface.
“It’s a very complicated mechanism that we quite frankly don’t know all the details about, but we’re getting more information,” said Dordick. “One thing that’s become clear with this study is that the larger the molecule, the better the fit. The more successful compounds are the larger sulfated polysaccharides that offer a greater number of sites on the molecules to trap the virus.”
Molecular modeling based on the binding study revealed sites on the spike protein where the heparin was able to interact, raising the prospects for similar sulfated polysaccharides.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Coronavirus decoy strategy
- Electronic attack updates boost Saab’s Gripen offer to Finlandon September 1, 2020 at 10:30 am
Saab used the Kauhava air show to announce fresh details about its Gripen E/F proposal for Finland’s HX fighter requirement, including the addition of a lightweight air-launched decoy missile ...
- IBio jumps into COVID-19 therapy race with Planet Biotech dealon August 28, 2020 at 9:30 am
ACE2-Fc works by using the ACE2 extracellular domain as a decoy to bind the coronavirus spike protein thereby preventing infection of healthy cells. ACE2, a protein found on the surface of healthy ...
- Raytheon Secures $22M Deal to Support MALD Flight Vehicleon August 24, 2020 at 7:16 am
Raytheon Technologies Corporation’s RTX Missiles and Defense (RMB) unit has recently secured a $21.8-million contract for providing sustainment services associated with the ADM-160B, ADM-160C and C-1 ...
- Raytheon Secures $22M Deal to Support MALD Flight Vehicleon August 24, 2020 at 6:12 am
The Miniature Air Launched Decoy (MALD) is a small unmanned air ... emerging to play a pivotal role in a nation’s defense strategy. With the United States being the world’s largest weapons ...
- COVID-19 Virus Uses Decoy Strategy to Evade Immune Systemon August 17, 2020 at 1:48 am
New Zealand scientists have discovered more about how viruses operate and can evade the immune system. Also Read - COVID-19: India's Death Toll Crosses 50,000-mark, Cases Surpass 26 Lakh | Key ...
Go deeper with Google Headlines on:
Coronavirus decoy strategy
Go deeper with Bing News on:
- Blood collection technique, anticoagulants and storing temperature have minor effects on the isolation of polymorphonuclear neutrophilson September 4, 2020 at 2:20 am
In the isolation of polymorphonuclear neutrophils (PMNs) the technique and other external factors can have great influence on the quality and quantity of isolated neutrophils. To elucidate the ...
- Heparin Market Estimated to Reach US$ 14 Billion By 2026 – Says, Coherent Market Insightson September 3, 2020 at 3:32 am
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of ...
- Heparin Sales Market Forecast Revised in a New Big Market Research Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2019on August 28, 2020 at 10:02 am
The scope of the report includes a detailed study of global and regional markets on Heparin sales market with the ...
- Global Heparin Market 2020-2024 | Evolving Opportunities with Aspen Pharmacare Holdings Ltd. and Baxter International Inc. | Technavioon August 27, 2020 at 5:00 pm
Technavio has been monitoring the global heparin market since 2015 and the market is poised to grow by USD 941.2 million during 2020-2024, progressing at a CAGR of almost 3% during the forecast ...
- Anticoagulation therapy associated with improved survival among COVID-19 patientson August 26, 2020 at 11:24 pm
Early in the COVID-19 pandemic, Mount Sinai researchers were among the first to show that anticoagulation therapy was associated with improved survival among hospitalized COVID-19 patients ...